Anyone who remembers the days of Flamel and Sky Pharma knows that the promise of nano drug delivery never really panned out for retail investors. These two firms promised to transform healthcare ...
It may sound like science fiction, but there was a time when people were optimistic about the future. Perhaps no other decade embodies that optimism than the 1960s, though maybe it was all of the...
They say good things come in small packages. Like Herve Villechaize, the French actor who played Tattoo on Fantasy Island. The idiom also applies to drugs. No, we’re not talking about the littl...
If you’re lucky enough to raise funding for your startup, you will then need to contend with new stakeholders that want to see “an exit”. When we refer to an exit, we refer to an event th...
It’s hard to say just how many publicly traded stocks we’ve covered so far on Nanalyze, but we’d guess that around 40% of our articles involve a publicly traded stock that has some degree o...
At the CB Insights fintech conference that wrapped up recently, an interesting fellow named Michael Novogratz made the remark that “Great bubbles occur around stories that are going to happen�...
Nanotechnology was all the rage back in 2004 when George Dubya Bush signed the Nanotechnology Research and Development Act and investors caught wind of a potential opportunity. This, of course, p...
In May of last year, we published an article titled “What if 3D Printing Was 1000X Faster” which talked about a 3D printing company called Carbon 3D which is looking to completely disrupt 3D...
For a majority of the people in this world who were fortunate enough to receive vaccinations, there are probably still some lingering unpleasant memories of being stuck with needles as a child. O...
In August of last year, we highlighted a nano drug delivery company called BIND Therapeutics (NASDAQ:BIND), a company with strong pharma partnerships and an experienced management team. While BIN...